Navigation Links
Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
Date:11/12/2009

PRINCETON, N.J. and SAN DIEGO, Nov. 12 /PRNewswire/ -- Tobira Therapeutics, a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two double-blind, placebo-controlled studies of TBR-652 in eighty-four healthy volunteers. The two studies, a single-ascending dose (SAD) study and the multiple-ascending dose (MAD) study, were undertaken to assess the pharmacokinetics, safety and tolerability of TBR-652 in two tablet formulations under fasted and fed conditions, respectively. In the SAD study 2 cohorts of 12 subjects were randomized per dose level; each subject received up to 3 single escalating doses of study drug. Dosing followed an overnight fast of at least 8 hours. In the MAD study, 5 dose groups of 12 subjects each were randomized to receive drug daily for 10 days. Doses were either in the same formulation as the SAD study (F1) or a newer formulation (F2). Doses were taken within 10 minutes after completion of a standard high-fat breakfast. Subjects in both studies were followed for 10 days after the last dose of TBR-652.

TBR-652 was readily absorbed in both tablet formulations achieving mean peak plasma concentrations in 4-6 hours. A 25 mg/day F1 or F2 tablet achieved plasma exposures greater than the target therapeutic level of 2ng/mL projected from in vitro studies of TBR-652. TBR-652 was eliminated from plasma with linear kinetics and similar half-lives (mean approximately 35-40 hours) across dose levels. This elimination half-life is sufficiently long to support once-daily dosing.

TBR-652 was well-tolerated at single daily doses up to 800 mg and once-daily doses of up to 200 mg for 10 days. Headache, diarrhea, abdominal pain and nausea were the most commonly encountered treatment-emergent events; all AEs resolved by the end of both studies. "The results from these two Phase II studies provide further basis for the continued development of TBR-652 for the treatment of HIV," said James Sapirstein, CEO. "Providing patients with well-tolerated, once-daily dosing options is a priority with our development programs. We look forward to the results from our on-going proof of concept trial of TBR-652."

These data were presented at the 12th( )European AIDS Conference (EACS), held November 11-14, 2009 in Cologne, Germany. The poster presentation can be viewed at www.tobiratherapeutics.com.

About Tobira Therapeutics

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

    Contact:
    James Sapirstein
    Tobira Therapeutics
    jsapirstein@tobiratherapeutics.com
    Tel: 609-897-1102
    www.tobiratherapeutics.com

SOURCE Tobira Therapeutics Inc.


'/>"/>
SOURCE Tobira Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV
2. Tobira Therapeutics Inc. Receives US Patent for TBR-652
3. Reportlinker Adds Pain Therapeutics 2005: Market Dynamics and Outlook
4. Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
5. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
6. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
7. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
8. Echo Therapeutics Announces Significant Advance in Development of its One-Piece, Needle Free Symphony tCGM Biosensor
9. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
10. Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
11. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... June 5, 2017 The Cincinnati ... Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded a ... . Results are based on an employee survey ... health and workplace improvement. The survey measures several aspects of ... ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... data solutions, today announced that it will be presenting at the ... 8:00 AM PT. Erez Raphael , CEO, of DarioHealth will ... conference will be held on June 6th & 7th, 2017 at ... in the small / micro-cap space. ...
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
Breaking Medicine Technology:
(Date:6/27/2017)... Simi Valley, CA (PRWEB) , ... June 27, 2017 , ... ... deployed since 2001 suffer from PTSD. Yet less than 20% will receive adequate care ... of those with PTSD won't receive any care at all. And left untreated, veterans ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... Antoine Dental Center is now ... standard in tooth replacement and act as a support for prosthetic teeth, such as crowns, ... the existing bone and becomes a sturdy, lasting new root for the tooth. , ...
(Date:6/26/2017)... Lake Tahoe, CA (PRWEB) , ... June 26, 2017 , ... ... seeking 10,000 qualified mental health professionals in every state across the country to join ... an easy and rewarding way for therapists to reach a substantially greater number of ...
(Date:6/25/2017)... ... , ... Create a feel-good lyric music video in Final Cut Pro X with ProLyric from ... write in the lyrics to any song. ProLyric flies in the text for each section ... can be added modularly for optimal control. ProLyric makes editing any music video or text-based ...
(Date:6/25/2017)... , ... June 25, 2017 , ... June is Men’s Health Month and ... most common cancer among men in the U.S. and the third most common cause of ... estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
Breaking Medicine News(10 mins):